Skip to content

Swiss Intravenous and Intra-arterial Thrombolysis for Treatment of Acute Ischemic Stroke Registry

Swiss Intravenous and Intra-arterial Thrombolysis for Treatment of Acute Ischemic Stroke Registry (SWISS)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00811538
Acronym
SWISS
Enrollment
1476
Registered
2008-12-19
Start date
2007-12-31
Completion date
2015-12-31
Last updated
2016-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Keywords

ischemic stroke, endovascular treatment, Thrombolysis, outcome

Brief summary

The clinical and radiological data of patients with an acute ischemic stroke treated with intravenous thrombolysis (IVT) or intraarterial thrombolysis (IAT) in a Swiss stroke unit are assessed in a Swiss Multicenter Thrombolysis Registry. Like in clinical routine, a clinical evaluation takes place in a 3-months follow-up. Furthermore quality of life is assessed with a standardized questionnaire. The aim of the registry is to compare the safety and efficacy of IVT and IAT in patients with acute ischemic stroke. The registry also helps to improve in-hospital-management of stroke patients.

Detailed description

Background: Intravenous thrombolysis (IVT) and intra-arterial thrombolysis (IAT) have been shown to be effective treatments for acute stroke in controlled randomized trials and meta-analyses. However, prospective studies comparing IVT and IAT have not been performed, and it is not known which patients benefit more from IVT or IAT. Non-invasive neurovascular imaging techniques such as magnetic resonance angiography (MRA) or computed tomography angiography (CTA) have the potential to improve patient selection for the optimal mode of thrombolytic therapy and provide data of pre-treatment neurovascular findings of patients treated with IVT. IAT series have identified several prognostic factors for favourable or poor outcome predictors such as vessel recanalization, location of the vascular occlusion or NIHSS at admission. Additional studies have shown that recanalization rates in patients with central ves-sel occlusions such as middle cerebral artery (MCA) main stem or MCA main branch or basilar artery (BA) is higher when treated with IAT compared to IVT. Therefore, the investigators hypothesize that IAT might be more efficacious in these patients. Objective: Prospective observational multicenter registry with the following aims: To compare the safety and efficacy of IAT and IVT in patients with acute ischemic stroke. To improve safety of IAT and IVT by monitoring the in-hospital management. Methods: Consecutive patients with acute ischemic stroke who are treated with IVT or IAT within 6 hours of symptom onset in a Swiss stroke unit will be eligible for this registry. Patients are given either intravenous rt-PA or receive IAT such as intra-arterial urokinase, intra-arterial rt-PA or mechanical endovascular recanalization techniques. Patient involvement in the registry shall not influence any treatment decision. Patients will undergo a complete diagnostic work up including a clinical neurological examination using the National Institutes of Health Stroke Scale (NIHSS) score on admission, laboratory examination, brain and neurovascular imaging, echocardiography, 24-hours ECG to determine stroke etiology using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. The treating physician will initiate secondary prevention of stroke as soon as possible. All patients will be examined by CT and CTA or MRI and MRA on day 1 and in any case of clinical deterioration to exclude intracranial haemorrhage and to assess recanalization of the occluded vessel (using the thrombolysis in myocardial infarction (TIMI) grading system). Clinical outcome will be evaluated on day 1 and at 3 months using the National Institute of Health Stroke Scale (NIHSS) score, modified Rankin Scale score (mRS), Barthel Index (BI), and assessing adverse events and quality of life. The proportion of patients with favourable outcome (mRS 0 to 2) at 3 months after IVT and IAT will serve as the primary outcome measure. In addition, subgroup analyses will be performed stratified by NIHSS, location of vessel occlusion, time to hospital admission and time to treatment. Secondary outcome measures will include quality of life and the proportion of patients with an excellent outcome (mRS 0 or 1) at 3 months, BI 75 to 100 at 3 months, mortality at 3 months, rapid neurological improvement during the first 24 hours, complete or partial recanalization, and symptomatic intracranial haemorrhage.

Interventions

i.V. thrombolysis with rtPa

PROCEDUREIntraarterial Thrombolysis

Endovascular treatment with i.a. Urokinase or i.a. rtPA or mechanical recanalization techniques

Sponsors

Swiss Heart Foundation
CollaboratorOTHER
University of Zurich
CollaboratorOTHER
University Hospital, Basel, Switzerland
CollaboratorOTHER
University Hospital, Geneva
CollaboratorOTHER
University of Lausanne Hospitals
CollaboratorOTHER
Kantonsspital Aarau
CollaboratorOTHER
Cantonal Hospital of St. Gallen
CollaboratorOTHER
Triemli Hospital
CollaboratorOTHER
Insel Gruppe AG, University Hospital Bern
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Intracranial arterial occlusion confirmed by conventional angiography, MRA or CTA * National Institute of health Stroke Scale (NIHSS) score ≥ 4 or isolated aphasia or hemianopia * Time to treatment \< 6 hours

Exclusion criteria

* Intracranial haemorrhage on CT scn or MRI * History of intracranial haemorrhage or subarachnoid haemorrhage * Platelet count \< 100'000 * International normalized ration (INR) \> 1.5 * Partial thromboplastin time (PTT) \> 1.5 times the normal value * Known hereditary of acquired haemorrhagic diathesis * Pre-existing neurological deficit (mRS\>2) * Previous stroke that might interfere with the neurological assessment (mRS \>2) * Active gastric ulcer * Major trauma within the preceding 3 months * Major surgery within the past 4 weeks * Childbirth within the previous 4 weeks * Pregnancy * Uncontrolled hypertension (\>185/10 on repeated measures despite antihypertensive medication) * Severe systemic disease with poor prognosis (e.g. cancer, severe heart failure) * Intracranial neoplasm * Combined IVT and IAT * Combined Intravenous and Ultrasound Thrombolysis

Design outcomes

Primary

MeasureTime frame
overall frequency of favourable clinical outcome (modified Rankin Scale 0 to 2), and unfavourable clinical outcome or death (modified Rankin Scale 3 to 6)Day 90

Secondary

MeasureTime frame
Excellent functional clinical outcome (modified Rankin Scale 0 or 1) and quality of life (measured by EuroQol and Stroke specific Quality of Life Scale)Day 90
All causes of mortalityDay 90
subgroup analyses will be performed stratified by NIHSS scoreDay 90
Complete or partial recanalization of the occluded artery (TIMI grade 2 or 3) assessed by CTA or MRA.Day 1
Symptomatic intracranial haemorrhages up to 24 hours after thrombolysis defined as homogeneous areas of haemorrhage, with or without mass effect or intraventricular extension with neurological deteriorationDay 1
Proportion of patients with rapid neurological improvement (more than 4 points on the NIHSS) during the first 24 hours after thrombolysis.Day 1

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026